Nanobiotix (NASDAQ:NBTX) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Nanobiotix (NASDAQ:NBTX) in a research report report published on Friday morning, Zacks.com reports.

Nanobiotix Price Performance

Shares of NBTX opened at $5.81 on Friday. Nanobiotix has a 1-year low of $1.75 and a 1-year high of $11.00. The firm has a fifty day moving average price of $6.26 and a 200 day moving average price of $6.54.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nanobiotix stock. Johnson & Johnson bought a new stake in Nanobiotix S.A. (NASDAQ:NBTX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 959,637 shares of the company’s stock, valued at approximately $8,397,000. Nanobiotix accounts for approximately 3.1% of Johnson & Johnson’s portfolio, making the stock its 9th biggest position. Johnson & Johnson owned approximately 2.65% of Nanobiotix at the end of the most recent quarter. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.